vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and TRIMAS CORP (TRS). Click either name above to swap in a different company.
TRIMAS CORP is the larger business by last-quarter revenue ($256.5M vs $168.4M, roughly 1.5× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 3.8%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 3.3%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Trimas Corp is a diversified industrial manufacturing enterprise that designs, produces and distributes a wide portfolio of engineered products, including specialized fasteners, aerospace components, custom packaging solutions, and consumer & industrial hardware. It primarily serves aerospace, automotive, construction, consumer goods and industrial sectors, with core operations across North America and selected global markets.
ESPR vs TRS — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $256.5M |
| Net Profit | — | $81.7M |
| Gross Margin | — | 12.8% |
| Operating Margin | 50.6% | 5.7% |
| Net Margin | — | 31.9% |
| Revenue YoY | 143.7% | 3.8% |
| Net Profit YoY | — | 236.9% |
| EPS (diluted) | $0.32 | $2.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $256.5M | ||
| Q4 25 | $168.4M | $-140.0M | ||
| Q3 25 | $87.3M | $269.3M | ||
| Q2 25 | $82.4M | $274.8M | ||
| Q1 25 | $65.0M | $241.7M | ||
| Q4 24 | $69.1M | $-66.2M | ||
| Q3 24 | $51.6M | $229.4M | ||
| Q2 24 | $73.8M | $240.5M |
| Q1 26 | — | $81.7M | ||
| Q4 25 | — | $81.7M | ||
| Q3 25 | $-31.3M | $9.3M | ||
| Q2 25 | $-12.7M | $16.7M | ||
| Q1 25 | $-40.5M | $12.4M | ||
| Q4 24 | — | $5.6M | ||
| Q3 24 | $-29.5M | $2.5M | ||
| Q2 24 | $-61.9M | $10.9M |
| Q1 26 | — | 12.8% | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 12.8% | ||
| Q2 25 | — | 13.8% | ||
| Q1 25 | — | 13.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 15.4% | ||
| Q2 24 | — | 14.4% |
| Q1 26 | — | 5.7% | ||
| Q4 25 | 50.6% | — | ||
| Q3 25 | -11.4% | 6.2% | ||
| Q2 25 | 8.6% | 9.9% | ||
| Q1 25 | -34.0% | 9.0% | ||
| Q4 24 | -6.4% | — | ||
| Q3 24 | -31.0% | 3.6% | ||
| Q2 24 | 3.5% | 7.4% |
| Q1 26 | — | 31.9% | ||
| Q4 25 | — | -58.4% | ||
| Q3 25 | -35.9% | 3.5% | ||
| Q2 25 | -15.4% | 6.1% | ||
| Q1 25 | -62.2% | 5.1% | ||
| Q4 24 | — | -8.5% | ||
| Q3 24 | -57.2% | 1.1% | ||
| Q2 24 | -83.9% | 4.5% |
| Q1 26 | — | $2.03 | ||
| Q4 25 | $0.32 | $2.01 | ||
| Q3 25 | $-0.16 | $0.23 | ||
| Q2 25 | $-0.06 | $0.41 | ||
| Q1 25 | $-0.21 | $0.30 | ||
| Q4 24 | $-0.14 | $0.14 | ||
| Q3 24 | $-0.15 | $0.06 | ||
| Q2 24 | $-0.33 | $0.27 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $30.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $705.6M |
| Total Assets | $465.9M | $1.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $30.0M | ||
| Q4 25 | $167.9M | $30.0M | ||
| Q3 25 | $92.4M | $33.6M | ||
| Q2 25 | $86.1M | $30.3M | ||
| Q1 25 | $114.6M | $32.7M | ||
| Q4 24 | $144.8M | $23.1M | ||
| Q3 24 | $144.7M | $26.9M | ||
| Q2 24 | $189.3M | $35.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | $469.2M | ||
| Q3 25 | — | $407.1M | ||
| Q2 25 | — | $424.5M | ||
| Q1 25 | — | $434.2M | ||
| Q4 24 | — | $398.1M | ||
| Q3 24 | — | $409.9M | ||
| Q2 24 | — | $427.4M |
| Q1 26 | — | $705.6M | ||
| Q4 25 | $-302.0M | $705.6M | ||
| Q3 25 | $-451.4M | $725.0M | ||
| Q2 25 | $-433.5M | $715.3M | ||
| Q1 25 | $-426.2M | $686.6M | ||
| Q4 24 | $-388.7M | $667.3M | ||
| Q3 24 | $-370.2M | $682.8M | ||
| Q2 24 | $-344.2M | $675.9M |
| Q1 26 | — | $1.5B | ||
| Q4 25 | $465.9M | $1.5B | ||
| Q3 25 | $364.0M | $1.4B | ||
| Q2 25 | $347.1M | $1.4B | ||
| Q1 25 | $324.0M | $1.4B | ||
| Q4 24 | $343.8M | $1.3B | ||
| Q3 24 | $314.1M | $1.4B | ||
| Q2 24 | $352.3M | $1.4B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.66× | ||
| Q3 25 | — | 0.56× | ||
| Q2 25 | — | 0.59× | ||
| Q1 25 | — | 0.63× | ||
| Q4 24 | — | 0.60× | ||
| Q3 24 | — | 0.60× | ||
| Q2 24 | — | 0.63× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $117.5M |
| Free Cash FlowOCF − Capex | — | $36.8M |
| FCF MarginFCF / Revenue | — | 14.4% |
| Capex IntensityCapex / Revenue | 0.0% | 18.9% |
| Cash ConversionOCF / Net Profit | — | 1.44× |
| TTM Free Cash FlowTrailing 4 quarters | — | $109.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $117.5M | ||
| Q4 25 | $45.2M | $41.5M | ||
| Q3 25 | $-4.3M | $36.5M | ||
| Q2 25 | $-31.4M | $30.3M | ||
| Q1 25 | $-22.6M | $9.2M | ||
| Q4 24 | $-35.0M | $27.1M | ||
| Q3 24 | $-35.3M | $22.0M | ||
| Q2 24 | $-7.2M | $18.4M |
| Q1 26 | — | $36.8M | ||
| Q4 25 | — | $36.8M | ||
| Q3 25 | — | $22.8M | ||
| Q2 25 | — | $13.2M | ||
| Q1 25 | — | $-3.8M | ||
| Q4 24 | — | $12.1M | ||
| Q3 24 | $-35.5M | $10.2M | ||
| Q2 24 | $-7.3M | $7.5M |
| Q1 26 | — | 14.4% | ||
| Q4 25 | — | -26.3% | ||
| Q3 25 | — | 8.5% | ||
| Q2 25 | — | 4.8% | ||
| Q1 25 | — | -1.6% | ||
| Q4 24 | — | -18.3% | ||
| Q3 24 | -68.7% | 4.4% | ||
| Q2 24 | -9.9% | 3.1% |
| Q1 26 | — | 18.9% | ||
| Q4 25 | 0.0% | -3.4% | ||
| Q3 25 | 0.0% | 5.1% | ||
| Q2 25 | 0.0% | 6.2% | ||
| Q1 25 | 0.0% | 5.4% | ||
| Q4 24 | 0.0% | -22.6% | ||
| Q3 24 | 0.3% | 5.2% | ||
| Q2 24 | 0.1% | 4.5% |
| Q1 26 | — | 1.44× | ||
| Q4 25 | — | 0.51× | ||
| Q3 25 | — | 3.92× | ||
| Q2 25 | — | 1.81× | ||
| Q1 25 | — | 0.74× | ||
| Q4 24 | — | 4.80× | ||
| Q3 24 | — | 8.71× | ||
| Q2 24 | — | 1.68× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
TRS
Segment breakdown not available.
